| Objective: To evaluate the clinical efficacy and safety of Wusunsawurile in the treatment of Wusunsa disease(cerebral infarction convalescence stage).Methods: A total of 60 outpatients and inpatients meeting the diagnostic criteria in the five-therapy encephalopathy department and traditional internal therapy Department of Inner Mongolia International Mongolian Hospital from October 2021 to February 2023 were selected and randomly divided into control group and experimental group with 30 patients in each group.All patients in 2 groups received conventional basic treatment drugs aspirin enteric-coated tablets(once a day,100mg/ day),atorvastatin calcium tablets(once a day,20mg/ day),control group plus Zhenbao Pill Ⅱ(once a day,15 capsules/time),experimental group plus Wusunsawurile(once a day,15 capsules/time),treatment for 4 weeks.NIHSS score,modified Rankin scale,Barthel index and Mongolian Syndrome Evaluation Scale were observed before treatment and at the second and fourth week of treatment.Safety evaluation was used for blood routine,urine routine,liver function,kidney function,electrocardiogram and other items before and after treatment.Statistical software SPSS25.0 was used to process the obtained data.Result:1.There was no statistical difference between the two groups due to gender,age and other data(P>0.05),were comparable between groups.2.There were no significant differences in NIHSS score,modified Rankin Scale,Barthel index and Mongolian Syndrome Evaluation Scale between the two groups(P>0.05),were comparable between groups.3.NIHSS score analysis: NIHSS score of the two groups decreased significantly after treatment,and there was a statistically significant difference compared with before treatment(P< 0.01),indicating that the two groups were effective in the treatment of cerebral infarction convalescent nerve function recovery.There was no significant difference between the two groups after treatment(P>0.05),indicating that the experimental group and the control group were similar in the treatment of cerebral infarction convalescent neurological function recovery.4.Analysis of the modified Rankin scale: After treatment,the modified Rankin scale in both groups decreased significantly,showing statistically significant differences compared with before treatment(P<0.01),indicating that both groups were effective in improving the degree of disability during the convalescence of cerebral infarction.There was no significant difference between the two groups after treatment(P>0.05),indicating that the experimental group and the control group were similar in improving the degree of disability during the convalescence of cerebral infarction.5.Barthel index analysis: The Barthel index of the two groups increased significantly after treatment,and there was a statistically significant difference compared with before treatment(P<0.01),indicating that both groups were effective in the treatment of cerebral infarction convalescent daily living ability.There was no significant difference between the two groups after treatment(P>0.05),indicating that the experimental group and the control group were similar in the treatment of cerebral infarction in the convalescence of daily living ability.6.Symptom evaluation scale analysis of Mongolian medicine: After treatment,the symptom evaluation scale of Mongolian medicine in the two groups decreased significantly,and the difference was statistically significant compared with that before treatment(P<0.01),indicating that both groups were effective in improving clinical symptoms during the convalescence of cerebral infarction.There was no significant difference between the two groups after treatment(P>0.05),indicating that the experimental group and the control group were similar in improving clinical symptoms during the convalescence of cerebral infarction.7.Analysis of efficacy: After treatment,the total effective rate of experimental group(83.33%)was slightly higher than that of control group(76.67%),and there was no statistical difference between groups(P>0.05).After treatment,the effective rate of Mongolian syndrome scale in experimental group(93.33%)was slightly higher than that in control group(86.67%),and there was no statistical difference between groups(P>0.05).The results showed that the experimental group and the control group had similar curative effect on the treatment of Wusunsa disease(cerebral infarction convalescence stage).Conclusion:Wusunsawurile can improve the neurological function defect,reduce the degree of disability,improve the ability of daily living,and effectively improve the clinical symptoms of the disease in patients with Wusunsa disease(cerebral infarction convalescence).The total effective rate was similar to the control group,and the safety was good. |
PDF Full Text Request